72.77
Schlusskurs vom Vortag:
$71.48
Offen:
$71.88
24-Stunden-Volumen:
1.23M
Relative Volume:
0.81
Marktkapitalisierung:
$7.49B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
57.75
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
+1.48%
1M Leistung:
-13.17%
6M Leistung:
+52.81%
1J Leistung:
+190.38%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CORT
Corcept Therapeutics Inc
|
72.77 | 7.49B | 628.56M | 141.82M | 142.60M | 1.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-06 | Hochstufung | Truist | Hold → Buy |
2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
2022-08-01 | Herabstufung | Truist | Buy → Hold |
2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
2022-01-28 | Eingeleitet | Truist | Buy |
2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
2019-09-24 | Eingeleitet | Jefferies | Buy |
2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
2018-08-10 | Bestätigt | Stifel | Hold |
2018-05-31 | Herabstufung | Stifel | Buy → Hold |
2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2017-08-31 | Eingeleitet | Stifel | Buy |
2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
2015-04-21 | Eingeleitet | FBR Capital | Outperform |
2014-01-13 | Herabstufung | Stifel | Buy → Hold |
2013-08-09 | Herabstufung | Janney | Buy → Neutral |
2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? - Yahoo Finance
BlackRock, Inc. Reduces Stake in Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? - Nasdaq
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS - GuruFocus
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
3 Healthcare Stocks That Concern Us - Yahoo Finance
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - MSN
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSEL - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 | CORT Stock News - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
Corcept: Maintaining Strong Buy Even After Q4 Revenue And Earnings Miss - Seeking Alpha
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus
Diabetes Care Publishes Results From Prevalence Phase Of Corcept'S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - marketscreener.com
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - Yahoo Finance
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know - Barchart.com
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Benzinga
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
Corcept therapeutics director Daniel Swisher sells stock for $154,484 By Investing.com - Investing.com Canada
Corcept therapeutics director Daniel Swisher sells stock for $154,484 - Investing.com
3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat
Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter - Yahoo
Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab - MarketScreener
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
Corcept begins trial for ovarian cancer treatment By Investing.com - Investing.com India
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Corcept Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CORT - Benzinga
Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept therapeutics officer sells $20.2 million in stock By Investing.com - Investing.com Australia
Piper Sandler lifts Corcept stock target to $131 post-study By Investing.com - Investing.com UK
Corcept Therapeutics’ chief development officer sells $77,639 in stock By Investing.com - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com Australia
Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada
Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com
Corcept therapeutics president sells shares worth $10.1 million - Investing.com
Corcept therapeutics officer sells $20.2 million in stock - Investing.com
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance
Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN
Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada
Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus
Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus
U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's
Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus
Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):